Sanofi-Aventis Given “Buy” Rating at TheStreet (SNY)
“Sanofi (SNY) has been reiterated by TheStreet Ratings as a buy with a ratings score of B . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
,” the firm’s analyst commented.
Sanofi-Aventis traded up 2.27% on Friday, hitting $48.72. Sanofi-Aventis has a 52-week low of $33.03 and a 52-week high of $49.70. The stock’s 50-day moving average is currently $48.00. The company has a market cap of $128.7 billion and a price-to-earnings ratio of 19.55.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays Capital downgraded shares of Sanofi-Aventis from an overweight rating to an equal weight rating in a research note to investors on Tuesday, January 29th. Separately, analysts at Goldman Sachs upgraded shares of Sanofi-Aventis from a conviction sell rating to a neutral rating in a research note to investors on Monday, January 28th. Finally, analysts at Zacks reiterated a neutral rating on shares of Sanofi-Aventis in a research note to investors on Friday, December 28th. They now have a $50.00 price target on the stock.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.